Loading…
Reported covered position: Health Insurance Specialist: CMS; Health Policy Advisor: U.S. Senator Al Franken; Health Insurance Specialist: CMS; Program Analyst: HHS
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Mikaela Naylon Give Kids a Chance Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Reintroduction of Medicaid VBPs for Patients (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). MDRP. CMMI. Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Reintroduction of the Patient Access Act. Bipartisan Health Care Act (S. 891). NIH Funding.
Mikaela Naylon Give Kids a Chance Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ALLIANCE FOR REGENERATIVE MEDICINE via ALLIANCE FOR REGENERATIVE MEDICINE
2025 · third_quarter · Q3
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Source: Senate LDA
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Mikaela Naylon Give Kids a Chance Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Accelerating Kids’ Access to Care Act of 2025
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Reintroduction of Medicaid VBPs for Patients (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). MDRP. CMMI. Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Reintroduction of the Patient Access Act. Bipartisan Health Care Act (S. 891). NIH Funding.
Accelerating Kids’ Access to Care Act of 2025
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Accelerating Kids’ Access to Care Act of 2025
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Reintroduction of Medicaid VBPs for Patients (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). MDRP. CMMI. Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Reintroduction of the Patient Access Act. Bipartisan Health Care Act (S. 891). NIH Funding.
Bipartisan Health Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Reintroduction of Medicaid VBPs for Patients (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). MDRP. CMMI. Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Reintroduction of the Patient Access Act. Bipartisan Health Care Act (S. 891). NIH Funding.
Bipartisan Health Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Bipartisan Health Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Give Kids a Chance Act of 2025
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Give Kids a Chance Act of 2025
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Reintroduction of Medicaid VBPs for Patients (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). MDRP. CMMI. Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Reintroduction of the Patient Access Act. Bipartisan Health Care Act (S. 891). NIH Funding.
Give Kids a Chance Act of 2025
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Medicaid VBPs for Patients Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Medicaid VBPs for Patients (MVP) Act (H.R.2666/S.4204). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI. Creating Hope Reauthorization Act of 2024 (H.R.7384/S.4583). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Preventive Health Savings Act (H.R.766/S.114). Patient Access Act of 2024 (H.R.9184).
Medicaid VBPs for Patients Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Medicaid VBPs for Patients (MVP) Act (H.R.2666/S.4204). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI. Creating Hope Reauthorization Act of 2024 (H.R.7384/S.4583). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Preventive Health Savings Act (H.R.766/S.114). Patient Access Act of 2024 (H.R.9184).
Medicaid VBPs for Patients Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. MVP Act (H.R. 2666). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI.
Medicaid VBPs for Patients Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. MVP Act (H.R. 2666). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI.
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Medicaid VBPs for Patients (MVP) Act (H.R.2666/S.4204). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI. Creating Hope Reauthorization Act of 2024 (H.R.7384/S.4583). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Preventive Health Savings Act (H.R.766/S.114). Patient Access Act of 2024 (H.R.9184).
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. MVP Act (H.R. 2666). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI.
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Medicaid VBPs for Patients (MVP) Act (H.R.2666/S.4204). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI. Creating Hope Reauthorization Act of 2024 (H.R.7384/S.4583). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Preventive Health Savings Act (H.R.766/S.114). Patient Access Act of 2024 (H.R.9184).
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. MVP Act (H.R. 2666). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI.
Creating Hope Reauthorization Act of 2024
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Medicaid VBPs for Patients (MVP) Act (H.R.2666/S.4204). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI. Creating Hope Reauthorization Act of 2024 (H.R.7384/S.4583). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Preventive Health Savings Act (H.R.766/S.114). Patient Access Act of 2024 (H.R.9184).
Creating Hope Reauthorization Act of 2024
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Medicaid VBPs for Patients (MVP) Act (H.R.2666/S.4204). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI. Creating Hope Reauthorization Act of 2024 (H.R.7384/S.4583). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Preventive Health Savings Act (H.R.766/S.114). Patient Access Act of 2024 (H.R.9184).
Dr. Michael C. Burgess Preventive Health Savings Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Medicaid VBPs for Patients (MVP) Act (H.R.2666/S.4204). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI. Creating Hope Reauthorization Act of 2024 (H.R.7384/S.4583). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Preventive Health Savings Act (H.R.766/S.114). Patient Access Act of 2024 (H.R.9184).
Dr. Michael C. Burgess Preventive Health Savings Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Medicaid VBPs for Patients (MVP) Act (H.R.2666/S.4204). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI. Creating Hope Reauthorization Act of 2024 (H.R.7384/S.4583). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Preventive Health Savings Act (H.R.766/S.114). Patient Access Act of 2024 (H.R.9184).
Patient Access Act of 2024
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Medicaid VBPs for Patients (MVP) Act (H.R.2666/S.4204). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI. Creating Hope Reauthorization Act of 2024 (H.R.7384/S.4583). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Preventive Health Savings Act (H.R.766/S.114). Patient Access Act of 2024 (H.R.9184).
Patient Access Act of 2024
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Medicaid VBPs for Patients (MVP) Act (H.R.2666/S.4204). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI. Creating Hope Reauthorization Act of 2024 (H.R.7384/S.4583). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Preventive Health Savings Act (H.R.766/S.114). Patient Access Act of 2024 (H.R.9184).
Preventive Health Savings Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Medicaid VBPs for Patients (MVP) Act (H.R.2666/S.4204). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI. Creating Hope Reauthorization Act of 2024 (H.R.7384/S.4583). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Preventive Health Savings Act (H.R.766/S.114). Patient Access Act of 2024 (H.R.9184).
Preventive Health Savings Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Medicaid VBPs for Patients (MVP) Act (H.R.2666/S.4204). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI. Creating Hope Reauthorization Act of 2024 (H.R.7384/S.4583). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Preventive Health Savings Act (H.R.766/S.114). Patient Access Act of 2024 (H.R.9184).
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. MVP Act (H.R. 2666). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI.
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Medicaid VBPs for Patients (MVP) Act (H.R.2666/S.4204). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI. Creating Hope Reauthorization Act of 2024 (H.R.7384/S.4583). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Preventive Health Savings Act (H.R.766/S.114). Patient Access Act of 2024 (H.R.9184).
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Medicaid VBPs for Patients (MVP) Act (H.R.2666/S.4204). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI. Creating Hope Reauthorization Act of 2024 (H.R.7384/S.4583). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Preventive Health Savings Act (H.R.766/S.114). Patient Access Act of 2024 (H.R.9184).
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. MVP Act (H.R. 2666). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI.
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Medicaid VBPs for Patients (MVP) Act (H.R.2666/S.4204). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI. Creating Hope Reauthorization Act of 2024 (H.R.7384/S.4583). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Preventive Health Savings Act (H.R.766/S.114). Patient Access Act of 2024 (H.R.9184).
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Medicaid VBPs for Patients (MVP) Act (H.R.2666/S.4204). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI. Creating Hope Reauthorization Act of 2024 (H.R.7384/S.4583). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Preventive Health Savings Act (H.R.766/S.114). Patient Access Act of 2024 (H.R.9184).
Creating Hope Reauthorization Act of 2024
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Medicaid VBPs for Patients (MVP) Act (H.R.2666/S.4204). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI. Creating Hope Reauthorization Act of 2024 (H.R.7384/S.4583). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Preventive Health Savings Act (H.R.766/S.114). Patient Access Act of 2024 (H.R.9184).
Creating Hope Reauthorization Act of 2024
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Medicaid VBPs for Patients (MVP) Act (H.R.2666/S.4204). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI. Creating Hope Reauthorization Act of 2024 (H.R.7384/S.4583). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Preventive Health Savings Act (H.R.766/S.114). Patient Access Act of 2024 (H.R.9184).
Medicaid VBPs for Patients Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. MVP Act (H.R. 2666). Accelerating Kids Access to Care Act (S.2372/H.R.4758).
Medicaid VBPs for Patients Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. MVP Act (H.R. 2666). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI.
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. MVP Act (H.R. 2666). Accelerating Kids Access to Care Act (S.2372/H.R.4758).
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. MVP Act (H.R. 2666). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI.
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. MVP Act (H.R. 2666). Accelerating Kids Access to Care Act (S.2372/H.R.4758).
Accelerating Kids’ Access to Care Act
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: ALLIANCE FOR REGENERATIVE MEDICINE
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. MVP Act (H.R. 2666). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI.
ALLIANCE FOR REGENERATIVE MEDICINE via ALLIANCE FOR REGENERATIVE MEDICINE
2025 · second_quarter · Q2
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via ALLIANCE FOR REGENERATIVE MEDICINE
2025 · first_quarter · Q1
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Reintroduction of Medicaid VBPs for Patients (MVP) Act. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). MDRP. CMMI. Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Reintroduction of the Patient Access Act. Bipartisan Health Care Act (S. 891). NIH Funding.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ALLIANCE FOR REGENERATIVE MEDICINE via ALLIANCE FOR REGENERATIVE MEDICINE
2024 · fourth_quarter · Q4
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Medicaid VBPs for Patients (MVP) Act (H.R.2666/S.4204). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI. Creating Hope Reauthorization Act of 2024 (H.R.7384/S.4583). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Preventive Health Savings Act (H.R.766/S.114). Patient Access Act of 2024 (H.R.9184).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ALLIANCE FOR REGENERATIVE MEDICINE via ALLIANCE FOR REGENERATIVE MEDICINE
2024 · third_quarter · Q3
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. Medicaid VBPs for Patients (MVP) Act (H.R.2666/S.4204). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI. Creating Hope Reauthorization Act of 2024 (H.R.7384/S.4583). Rare Pediatric Disease Designation and Priority Review Voucher (PRV) Programs. Preventive Health Savings Act (H.R.766/S.114). Patient Access Act of 2024 (H.R.9184).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ALLIANCE FOR REGENERATIVE MEDICINE via ALLIANCE FOR REGENERATIVE MEDICINE
2024 · second_quarter · Q2
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. MVP Act (H.R. 2666). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ALLIANCE FOR REGENERATIVE MEDICINE via ALLIANCE FOR REGENERATIVE MEDICINE
2024 · first_quarter · Q1
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. MVP Act (H.R. 2666). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ALLIANCE FOR REGENERATIVE MEDICINE via ALLIANCE FOR REGENERATIVE MEDICINE
2023 · fourth_quarter · Q4
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. MVP Act (H.R. 2666). Accelerating Kids Access to Care Act (S.2372/H.R.4758). MDRP. CMMI.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ALLIANCE FOR REGENERATIVE MEDICINE via ALLIANCE FOR REGENERATIVE MEDICINE
2023 · third_quarter · Q3
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value Based Payment legislation. CMS policies regarding Value Based legislation. FDA appropriations. FDA staffing. Prescription Drug User Fee Act (PDUFA). Medicaid reimbursement. Provider credentialing. Medicare reimbursement. NTAP. MVP Act (H.R. 2666). Accelerating Kids Access to Care Act (S.2372/H.R.4758).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via ALLIANCE FOR REGENERATIVE MEDICINE
2023 · third_quarter · RA
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products, including: Value Based Payment legislation; CMS policies regarding Value Based legislation; FDA appropriations.
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products, including: Value Based Payment legislation; CMS policies regarding Value Based legislation; FDA appropriations.